To date, in HCC, miR-130b has been shown to promote CD133+ CSC tumorigenicity and self-renewal [18], whereas miR-181 inhibition reduces the number of EpCAM+ CSCs and tumor-initiating ability [19]. This evidence concerns the gene EPCAM and neoplasm.